Featured Research

from universities, journals, and other organizations

Tamoxifen’s Effectiveness May Be Compromised By Hot Flash Drug

Date:
December 3, 2003
Source:
Indiana University
Summary:
The effects of tamoxifen, a therapy used in the treatment and prevention of breast cancer, may be limited by the use of a commonly prescribed drug to prevent side effects of the treatment, according to a study published in the Dec. 3 issue of the Journal of the National Cancer Institute.

The effects of tamoxifen, a therapy used in the treatment and prevention of breast cancer, may be limited by the use of a commonly prescribed drug to prevent side effects of the treatment, according to a study published in the Dec. 3 issue of the Journal of the National Cancer Institute.

"Our study suggests that tamoxifen's metabolism, and possibly its effectiveness, can be modified by the genetic makeup of the person taking the drug and by the use of another drug prescribed to reduce tamoxifen-related hot flashes," says the study's senior author David Flockhart, M.D., Ph.D., director of the Division of Clinical Pharmacology at the Indiana University School of Medicine. "Our conclusions indicate that more extensive research is appropriate."

Tamoxifen, a drug that modifies the effect of estrogen on cells, is widely and effectively used in many women as part of standard therapy for those with breast cancer and those at high risk of developing the disease. For about 80 percent of the women who take tamoxifen, hot flashes are a side effect of the therapy and 45 percent of those women rate them as severe.

Drugs commonly prescribed to remedy the problem are new antidepressants, paroxetine and fluoxetine, which are selective serotonin reuptake inhibitors (SSRIs). SSRIs have been shown to inhibit the enzyme that breaks down tamoxifen into chemical agents called metabolites, including 4-hydroxy-tamoxifen, which was believed to be tamoxifen's most active metabolite.

Twelve women with a history of breast cancer, but no current evidence of the disease, were enrolled in a yearlong clinical trial. The women had to have taken tamoxifen for four weeks prior to enrolling in the trial, and remained on the therapy until the trial's conclusion. Each woman also took paroxetine for four weeks.

Extensive laboratory analysis of the women's blood plasma showed a significant decrease in a metabolite of tamoxifen after treatment with paroxetine.

The researchers discovered a previously unknown metabolite which they named endoxifen. It was found to be present in substantially higher concentrations than 4-hydroxy-tamoxifen in women taking tamoxifen. It was clear that the concentration of endoxifen in the plasma was altered when paroxetine was used.

Endoxifen concentrations were reduced from 24 percent to 64 percent, with a mean decrease of 56 percent. The difference in the percentages of endoxifen concentrations corresponds to variations in the genetic composition of the women. Researchers hypothesize that this variation also may be the reason tamoxifen is more effective in some patients than others.

###

The research was supported by a grant from the National Institute of General Medical Sciences, part of the National Institutes of Health. First author of the article was Vered Stearns, M.D., assistant professor of oncology, Breast Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine.


Story Source:

The above story is based on materials provided by Indiana University. Note: Materials may be edited for content and length.


Cite This Page:

Indiana University. "Tamoxifen’s Effectiveness May Be Compromised By Hot Flash Drug." ScienceDaily. ScienceDaily, 3 December 2003. <www.sciencedaily.com/releases/2003/12/031203080425.htm>.
Indiana University. (2003, December 3). Tamoxifen’s Effectiveness May Be Compromised By Hot Flash Drug. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2003/12/031203080425.htm
Indiana University. "Tamoxifen’s Effectiveness May Be Compromised By Hot Flash Drug." ScienceDaily. www.sciencedaily.com/releases/2003/12/031203080425.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins